Parkinson's disease
Mitochondrial DNA Damage May Serve as Biomarker of Parkinson's Disease
Researchers at Duke University detected mitochondrial DNA damage in Parkinson's patients with and without mutations in LRRK2, a well-known cause of the disease.
The assay could allow clinicians to diagnose synucleinopathies like Parkinson's disease without requiring a lumbar puncture to collect cerebrospinal fluid.
The test showed good accuracy for detecting the disease while also distinguishing different subtypes, suggesting it could help guide treatment in the future.
CND Life Sciences Closes $4.5M Series Seed 3 Financing Round
The company will use the funding to accelerate commercialization of its Syn-One test for identifying abnormal alpha-synuclein aggregation via skin biopsy.
CND Life Sciences, Beth Israel Ink Licensing Deal for Neurodegenerative Disease Test Technology
The agreement gives CND access to technologies key to CND's skin biopsy-based test for the hallmarks of the synucleinopathy family of neurodegenerative diseases.